Semaglutide: indexed trial records
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
This page carries 12 of the 5,682 records the literature query returned for Semaglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.
Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.
At a glance
- Class
- Incretin receptor agonists
- Receptor targets as recorded
- GLP-1 receptor
- Records indexed here
- 12
- Records returned by the query
- 5,682
- Publication years covered
- 2024–2025
- Query retrieved
- 2026-10-10
Shape of the indexed record set
| Record class | Records |
|---|---|
| Phase 3 | 3 |
| Phase 2 | 1 |
| Trial, no phase assigned | 3 |
| Not a registered trial record | 5 |
| Study model as assigned | Records |
|---|---|
| human trial | 10 |
| other | 2 |
Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.
Endpoint coverage
| Endpoint | Records for this compound | Records across all compounds in scope |
|---|---|---|
| Body weight and adiposity | 7 | 108 |
| Glycaemic control | 5 | 117 |
| Cardiovascular | 6 | 30 |
| Renal | 2 | 10 |
| Hepatic | 1 | 9 |
| Neurological | 0 | 18 |
1 of the 12 records here carry no subject heading from any endpoint set used on this site, so they appear under no endpoint.
Derived record-set tier
Human trial evidence
(INFERRED, derived from record counts)
Basis: 10 of 12 indexed records are interventional human trials by their own assigned publication type.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of
study quality or of consensus, and it does not rank one compound above another.
What the corpus does not carry for this compound
- Identity fields with no source retrieved: uniprot_id, sequence.
- Reported half-life: no source retrieved, so the value reads Unknown.
- Amounts reported in the cited literature: no row recorded.
- Adverse effects reported in the cited literature: no row recorded.
- Long-form mechanism: not written, because no source was read in full.
- Records the query returned that this corpus does not carry: 5,670.
An absent row records the absence of a retrieved report, never the absence of the thing itself.
Application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA213051, marketed as OZEMPIC, RYBELSUS). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
The records
Phase 3 — 3 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 3 | pmid:40305708 | 2025 | Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Liver; Humans; Liver Cirrhosis; Biopsy; Treatment Outcome; Injections, Subcutaneous; Drug Administration Schedule; Severity of Illness Index |
| 4 | pmid:40353578 | 2025 | Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England journal of medicine · Clinical Trial, Phase III, Comparative Study | human trial | Humans; Obesity; Body Weight; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Maximum Tolerated Dose |
| 12 | pmid:39476339 | 2024 | Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Humans; Arthralgia; Osteoarthritis, Knee; Obesity; Weight Loss; Pain Measurement; Body Mass Index; Combined Modality Therapy |
Phase 2 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 1 | pmid:39937469 | 2025 | Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial JAMA psychiatry · Clinical Trial, Phase II, research-article | human trial | Humans; Alcoholism; Treatment Outcome; Drug Administration Schedule; Double-Blind Method; Alcohol Drinking; Adult; Middle Aged |
Trial, no phase assigned — 3 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 2 | pmid:40162642 | 2025 | Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes The New England journal of medicine · Equivalence Trial, Multicenter Study | human trial | Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Administration, Oral; Follow-Up Studies; Double-Blind Method; Aged; Middle Aged |
| 5 | pmid:38587233 | 2024 | Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes The New England journal of medicine · Randomized Controlled Trial | human trial | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Double-Blind Method; Glucagon-Like Peptides; Heart Failure; Glucagon-Like Peptide-1 Receptor Agonists |
| 8 | pmid:38785209 | 2024 | Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England journal of medicine · Multicenter Study, Randomized Controlled Trial | human trial | Humans; Diabetic Nephropathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glomerular Filtration Rate; Injections, Subcutaneous; Double-Blind Method |
Not a registered trial record — 5 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 6 | pmid:38599221 | 2024 | Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, Non-U.S. Gov't, research-article | human trial | Humans; Obesity; Stroke Volume; Treatment Outcome; Double-Blind Method; Aged; Middle Aged; Female |
| 7 | pmid:38740993 | 2024 | Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature medicine · Research Support, Non-U.S. Gov't, research-article | human trial | Humans; Cardiovascular Diseases; Obesity; Weight Loss; Body Mass Index; Treatment Outcome; Double-Blind Method; Adult |
| 9 | pmid:38958939 | 2024 | Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide JAMA ophthalmology · research-article | other | Humans; Optic Neuropathy, Ischemic; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Incidence; Risk Factors; Retrospective Studies; Aged |
| 10 | pmid:38976257 | 2024 | Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA internal medicine · Comparative Study, Research Support, Non-U.S. Gov't | other | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Retrospective Studies; Cohort Studies; Adult; Aged |
| 11 | pmid:39222642 | 2024 | Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | human trial | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Treatment Outcome; Hospitalization; Aged; Middle Aged |
Where this page sits
Receptor targets
Curated pairs
- Cagrilintide and Semaglutide, side by side
- Liraglutide and Semaglutide, side by side
- Semaglutide and Tirzepatide, side by side
All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.
Review status
- Review tier
- High impact
- State
- Pending qualified review
- Compiled by
- automated pipeline
- Qualified clinical review
- None on record
Why this tier was assigned
- the name carries 1 Drugs@FDA application record(s), so readers may conflate it with an approved medicine
- 10 indexed record(s) are interventional human trials
- the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus
Checks the pipeline performed
- every cited source id resolves to a sources[] row on the entity
- every identifier is a well-formed PMID or DOI
- study model derived only from assigned MeSH headings and publication types
- banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
- unknown values render as the literal word Unknown
Checks the pipeline did not perform
- no full text was read
- no clinical appraisal of any study
- no assessment of whether the indexed set is representative of the literature
A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.
Sources
- PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487